DNLI
Price
$15.81
Change
+$0.32 (+2.07%)
Updated
Apr 25, 02:23 PM (EDT)
Capitalization
2.25B
18 days until earnings call
RGNX
Price
$9.10
Change
-$0.10 (-1.09%)
Updated
Apr 25, 02:46 PM (EDT)
Capitalization
461.08M
5 days until earnings call
Ad is loading...

DNLI vs RGNX

Header iconDNLI vs RGNX Comparison
Open Charts DNLI vs RGNXBanner chart's image
Denali Therapeutics
Price$15.81
Change+$0.32 (+2.07%)
Volume$603
Capitalization2.25B
REGENXBIO
Price$9.10
Change-$0.10 (-1.09%)
Volume$500
Capitalization461.08M
DNLI vs RGNX Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. RGNX commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and RGNX is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (DNLI: $15.49 vs. RGNX: $9.20)
Brand notoriety: DNLI and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 94% vs. RGNX: 82%
Market capitalization -- DNLI: $2.25B vs. RGNX: $461.08M
DNLI [@Biotechnology] is valued at $2.25B. RGNX’s [@Biotechnology] market capitalization is $461.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNLI and RGNX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while RGNX’s TA Score has 4 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 4 bearish.
  • RGNX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than RGNX.

Price Growth

DNLI (@Biotechnology) experienced а +21.59% price change this week, while RGNX (@Biotechnology) price change was +54.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.17%. For the same industry, the average monthly price growth was -4.24%, and the average quarterly price growth was -12.55%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+7.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.25B) has a higher market cap than RGNX($461M). RGNX YTD gains are higher at: 19.017 vs. DNLI (-23.994). RGNX has higher annual earnings (EBITDA): -198.23M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. RGNX (235M). DNLI has less debt than RGNX: DNLI (48.7M) vs RGNX (82M). RGNX has higher revenues than DNLI: RGNX (83.3M) vs DNLI (0).
DNLIRGNXDNLI / RGNX
Capitalization2.25B461M488%
EBITDA-492.89M-198.23M249%
Gain YTD-23.99419.017-126%
P/E RatioN/AN/A-
Revenue083.3M-
Total Cash832M235M354%
Total Debt48.7M82M59%
FUNDAMENTALS RATINGS
DNLI vs RGNX: Fundamental Ratings
DNLI
RGNX
OUTLOOK RATING
1..100
1716
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3995
PRICE GROWTH RATING
1..100
6456
P/E GROWTH RATING
1..100
9819
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (76) in the Biotechnology industry is in the same range as DNLI (94). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DNLI (100). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for RGNX (95). This means that DNLI’s stock grew somewhat faster than RGNX’s over the last 12 months.

RGNX's Price Growth Rating (56) in the Biotechnology industry is in the same range as DNLI (64). This means that RGNX’s stock grew similarly to DNLI’s over the last 12 months.

RGNX's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for DNLI (98). This means that RGNX’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIRGNX
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
74%
Declines
ODDS (%)
Bearish Trend 10 days ago
80%
Bearish Trend 9 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TDFAX7.57N/A
N/A
Transamerica Sustainable Equity Inc A
NLSIX18.67N/A
N/A
Neuberger Berman Long Short Instl
AEYMX11.38N/A
N/A
American Century Emerging Markets Y
RYBHX43.58N/A
N/A
Rydex S&P MidCap 400 Pure Growth H
AGGIX10.89N/A
N/A
American Century Focused Global Gr I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+4.17%
BEAM - DNLI
59%
Loosely correlated
+1.51%
RCKT - DNLI
57%
Loosely correlated
+4.06%
NTLA - DNLI
56%
Loosely correlated
+1.11%
ARWR - DNLI
56%
Loosely correlated
+2.54%
RGNX - DNLI
56%
Loosely correlated
+3.72%
More

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with RCKT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+3.72%
RCKT - RGNX
59%
Loosely correlated
+4.06%
DNLI - RGNX
54%
Loosely correlated
+4.17%
ARWR - RGNX
54%
Loosely correlated
+2.54%
NTLA - RGNX
53%
Loosely correlated
+1.11%
BEAM - RGNX
50%
Loosely correlated
+1.51%
More